A Novel Ultrahigh-Dose-Rate Proton Therapy Technology: Spot-Scanning Proton Arc Therapy + FLASH (SPLASH).


Journal

International journal of radiation oncology, biology, physics
ISSN: 1879-355X
Titre abrégé: Int J Radiat Oncol Biol Phys
Pays: United States
ID NLM: 7603616

Informations de publication

Date de publication:
01 11 2023
Historique:
received: 05 12 2022
revised: 10 04 2023
accepted: 08 05 2023
medline: 25 9 2023
pubmed: 18 5 2023
entrez: 17 5 2023
Statut: ppublish

Résumé

To take full advantage of FLASH dose rate (40 Gy/s) and high-dose conformity, we introduce a novel optimization and delivery technique, the spot-scanning proton arc therapy (SPArc) + FLASH (SPLASH). SPLASH framework was implemented in an open-source proton planning platform (MatRad, Department of Medical Physics in Radiation Oncology, German Cancer Research Center). It optimizes with the clinical dose-volume constraint based on dose distribution and the dose-average dose rate by minimizing the monitor unit constraint on spot weight and accelerator beam current sequentially, enabling the first dynamic arc therapy with voxel-based FLASH dose rate. This new optimization framework minimizes the overall cost function value combined with plan quality and voxel-based dose-rate constraints. Three representative cases (brain, liver, and prostate cancer) were used for testing purposes. Dose-volume histogram, dose-rate-volume histogram, and dose-rate map were compared among intensity modulated proton radiation therapy (IMPT), SPArc, and SPLASH. SPLASH/SPArc could offer superior plan quality over IMPT in terms of dose conformity. The dose-rate-volume histogram results indicated SPLASH could significantly improve V SPLASH offers the first voxel-based ultradose-rate and high-dose conformity treatment using proton beam therapy. Such a technique has the potential to fit the needs of a broad range of disease sites and simplify clinical workflow without applying a patient-specific ridge filter, which has never before been demonstrated.

Identifiants

pubmed: 37196836
pii: S0360-3016(23)00460-1
doi: 10.1016/j.ijrobp.2023.05.012
pii:
doi:

Substances chimiques

Protons 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

730-737

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Auteurs

Gang Liu (G)

Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430023 China. Electronic address: liugang9910@163.com.

Lewei Zhao (L)

Department of Radiation Oncology, Beaumont Health System, Royal Oak, Michigan.

Xiaoqiang Li (X)

Department of Radiation Oncology, Beaumont Health System, Royal Oak, Michigan.

Sheng Zhang (S)

Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430023 China. Electronic address: tonydppx@hotmail.com.

Shuyang Dai (S)

School of Mathematics and Statistics, Wuhan University, Wuhan 430072 China.

Xiliang Lu (X)

School of Mathematics and Statistics, Wuhan University, Wuhan 430072 China.

Xuanfeng Ding (X)

Department of Radiation Oncology, Beaumont Health System, Royal Oak, Michigan. Electronic address: Xuanfeng.Ding@beaumont.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH